Radovan Vrhovac

Zagreb, Croatia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Concurrent B-cell acute lymphoblastic leukemia and plasma cell neoplasm with plasmablastic features supporting divergent evolution from a shared precursor: a case report.

Concurrent B-cell acute lymphoblastic leukemia and plasma cell neoplasm with plasmablastic features supporting divergent evolution from a shared precursor: a case report.

Journal: Frontiers in oncology

Published: May 20, 2026

Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe - a physician survey.

Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe - a physician survey.

Journal: Antiviral therapy

Published: April 29, 2026

Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.

Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.

Journal: International journal of molecular sciences

Published: April 18, 2026

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Journal: Haematologica

Published: April 01, 2026

Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.

Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.

Journal: Bone marrow transplantation

Published: March 21, 2026

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Journal: Blood neoplasia

Published: February 20, 2026

Von Willebrand factor and factor VIII as potential biomarkers for diagnosis and disease monitoring in chronic graft-versus-host disease.

Von Willebrand factor and factor VIII as potential biomarkers for diagnosis and disease monitoring in chronic graft-versus-host disease.

Journal: Bone marrow transplantation

Published: December 10, 2025

G-CSF Priming of Haploidentical Bone Marrow: Effects on Cell Yield, Collection Efficiency, and Tolerogenic Graft Composition.

G-CSF Priming of Haploidentical Bone Marrow: Effects on Cell Yield, Collection Efficiency, and Tolerogenic Graft Composition.

Journal: Annals of transplantation

Published: November 18, 2025

Effect of vitamin D replacement on nutritional status and muscle strength in patients after allogeneic stem cell transplantation and chronic graft-versus-host disease.

Effect of vitamin D replacement on nutritional status and muscle strength in patients after allogeneic stem cell transplantation and chronic graft-versus-host disease.

Journal: Clinical nutrition ESPEN

Published: June 01, 2025

FLT3-ITD measurable residual disease from the QuANTUM-First trial.

FLT3-ITD measurable residual disease from the QuANTUM-First trial.

Journal: Blood advances

Published: March 10, 2025

FLT3-ITD measurable residual disease from the QuANTUM-First trial.

FLT3-ITD measurable residual disease from the QuANTUM-First trial.

Journal: Blood advances

Published: March 10, 2025

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.

Journal: Leukemia

Published: March 03, 2025

Showing 1-12 of 70

Last Updated: 09/26/2026